Caitlin John LLC Acquires New Holdings in Pfizer Inc. $PFE

Key Points

• Caitlin John LLC has acquired a new position in Pfizer Inc. by purchasing 12,478 shares valued at approximately $302,000.
• Pfizer reported a quarterly earnings per share of $0.78, exceeding analysts' expectations of $0.58, with quarterly revenue reaching $14.65 billion.
• Recent analyst ratings changes include a revision from "hold" to "buy" by Wall Street Zen, with a consensus price target for Pfizer set at $28.12.

Caitlin John LLC bought a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 12,478 shares of the biopharmaceutical company's stock, valued at approximately $302,000.

A number of other large investors have also bought and sold shares of PFE. McGlone Suttner Wealth Management Inc. lifted its holdings in shares of Pfizer by 6.4% in the second quarter. McGlone Suttner Wealth Management Inc. now owns 21,301 shares of the biopharmaceutical company's stock valued at $516,000 after purchasing an additional 1,278 shares in the last quarter. S.A. Mason LLC grew its stake in shares of Pfizer by 11.9% during the 2nd quarter. S.A. Mason LLC now owns 8,999 shares of the biopharmaceutical company's stock worth $218,000 after acquiring an additional 955 shares in the last quarter. U.S. Capital Wealth Advisors LLC grew its stake in shares of Pfizer by 15.5% during the 2nd quarter. U.S. Capital Wealth Advisors LLC now owns 461,949 shares of the biopharmaceutical company's stock worth $11,198,000 after acquiring an additional 61,977 shares in the last quarter. Lewis Asset Management LLC grew its stake in shares of Pfizer by 184.6% during the 2nd quarter. Lewis Asset Management LLC now owns 23,472 shares of the biopharmaceutical company's stock worth $569,000 after acquiring an additional 15,224 shares in the last quarter. Finally, Whitener Capital Management Inc. grew its stake in shares of Pfizer by 3.4% during the 2nd quarter. Whitener Capital Management Inc. now owns 75,089 shares of the biopharmaceutical company's stock worth $1,820,000 after acquiring an additional 2,476 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Pfizer Price Performance

PFE stock traded up $0.02 during midday trading on Monday, reaching $24.05. The company had a trading volume of 67,725,099 shares, compared to its average volume of 42,502,152. The company has a market capitalization of $136.74 billion, a price-to-earnings ratio of 12.79, a price-to-earnings-growth ratio of 0.78 and a beta of 0.55. The stock has a 50 day moving average price of $24.61 and a 200-day moving average price of $24.18. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $30.43. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.Pfizer's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were paid a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 7.2%. Pfizer's payout ratio is presently 91.49%.

Analysts Set New Price Targets

PFE has been the subject of several research reports. Wall Street Zen raised shares of Pfizer from a "hold" rating to a "buy" rating in a research note on Saturday. Berenberg Bank decreased their price target on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research note on Thursday, May 29th. Morgan Stanley raised their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research note on Wednesday, August 6th. Citigroup raised their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Finally, Bank of America raised their target price on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.